PROMETEO
Window Program
Combination of Talimogene Laherparepvec with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy
Phase 0
Status
Follow up
Tumour subtype:
HR+, TNBC
Scenario
Neoadjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Tomás Pascual, MD(Hospital Clínic de Barcelona)
